What question did this study set out to answer?

To assess the viability of platelet-neutrophil aggregates (PNA-MFI) as a novel biomarker for diagnosing coagulopathy and predicting disseminated intravascular coagulation (DIC) in sepsis.

March 25, 2026Open Access

Circulating Platelet–Neutrophil Aggregates as Novel Biomarker for Coagulopathy Diagnosis and Disseminated Intravascular Coagulation Prediction in Sepsis

Puntos clave

To assess the viability of platelet-neutrophil aggregates (PNA-MFI) as a novel biomarker for diagnosing coagulopathy and predicting disseminated intravascular coagulation (DIC) in sepsis.
Evaluated the platelet-neutrophil aggregate using PNA-MFI technology.
Conducted internal validation of the biomarker.
Discussed the need for external validation and multicenter studies before clinical use.
Identified PNA-MFI as a promising biomarker for sepsis-related coagulopathy.
Highlighted the necessity of further research to establish clinical relevance.

Resumen

PNA-MFI is a promising biomarker for SIC diagnosis and DIC prediction. While internally validated, external validation is essential prior to clinical implementation, and further multicenter studies are warranted to definitively establish its clinical value.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo